Among them, AZD8055 is an inhibitor of mTORC1 and mTORC2, and it is now believed that AZD8055 has antitumor activity in acute myeloma leukemia (Willems et al., 2012); BEZ235 is a PI3K/mTOR inhibitor that is believed to suppress the growth of tumor cells with PI3K mutations (Serra et al., 2008). Here, MTOR is linked to neoplasm.